非小细胞肺癌免疫治疗疗效预测生物标志物相关进展

Progress in Biomarker Prediction of Immunotherapy Efficacy in Non-small Cell Lung Cancer

肺癌在所有癌症相关病死率中居首位,占28%。目前针对肺癌治疗的方式也在不断进展,从传统意义上的化疗、放射治疗到靶向治疗,再到新兴的免疫治疗,使癌症治疗进入了一个新的时代。但免疫治疗并非能使所有患者获益,甚至有的患者出现“超进展”。因此应用生物标志物来预测免疫治疗疗效的研究备受关注,根据查阅相关文献,本文就目前有潜力预测免疫治疗在非小细胞肺癌疗效的生物标志物进行论述非小细胞肺癌使用免疫治疗药物的生物标志物进行描述。

Lung cancer still leads in cancer-related mortality,accounting for 28 percent of all cancer deaths.At present,the treatment of lung cancer is also progressing,from the traditional chemotherapy,radiotherapy to targeted therapy,and then to the emerging immunotherapy,so that cancer treatment has entered a new era.But not all patients benefit from immunotherapy,and some can even show"superprogression."Therefore,the research on biomarkers to predict the efficacy of immunotherapy has attracted much attention.Based on the review of relevant literature,this paper describes the current confirmed progress and the novel biomarkers that have the potential to guide the use of immunotherapy drugs in nonsmall cell lung cancer.